60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target lowered by analysts at Ascendiant Capital Markets from $3.00 to $2.80. They now have a "buy" rating on the stock.
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by analysts at Zacks Research to a "hold" rating.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results [Yahoo! Finance]